Please login to the form below

Not currently logged in
Email:
Password:

Hospira CEO joins board of Kythera

Michael Ball named director of aesthetic medicine specialist

Kythera Michael BallKythera Biopharmacueticals has appointed Hospira's CEO Michael Ball to the company's board of directors.

Ball has served as CEO at Hospira, creators of the first biosimilar to be launched in the EU, since 2011.

He joined the company following a 16-year stint at Botox developers Allergan, serving as president from 2006. His earlier roles at Allergan included president of pharmaceuticals and president for North America.

This experience in aesthetic products such as Botox will serve him well in his role at Kythera, with the company currently developing ATX-101 as an injectable treatment for the reduction of fat under the chin and around the neck. The drug is currently in phase III development.

"We are thrilled to have him on board,” commented Keith Leonard, Kythera's president and CEO. “His knowledge and perspective will support our mission to bring innovation to the growing area of aesthetic medicine."

2nd October 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics